Articles On Respiri (ASX:RSH)

When it comes to medication adherence, humans are strange beasts in that they will go out of their way not to take crucial therapies in the manner intended. In the case of asthma and chronic obstructive pulmonary disease (COPD), ‘puffer’ co...

Highlights ASX-listed Funtastic (FUN) active in the consumer products space, recently merged with another company Azure Minerals (AZS) operating in the exploration sector, known for lithium-related developments Family Zone C...

Nova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the back of a flagged US pharmaceutical tariff Flu vaccines don’t give you autism, but do they work? Recce is raising up to $15.8 million to fund...

ASX takes a hit as energy sector sinks Gold miners shine, Star entertainment gets a lifeline Spacetalk shifts gears with AI health tech partnership   The ASX had a rough Thursday, slipping by 0.57% with the energy sector, in particular, f...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Highlight Respiri rebrands to Vitasora after raising $4 million to boost growth in the US market. Truscreen secures a strategic partnership in China, facing near-term revenue shifts. Lumos Diagnostics sees revenue increase with new de...

ASX hovers near one-month low, dragged by GYG and banks Domain soars on takeover bid RBA’s bullock admits slow rate hikes, while Alibaba rebounds   The ASX had a rough afternoon on Friday, with the market closing near its one-month low. D...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX healthcare shares are higher in early trading on Tuesday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) up 0.34% while the broader S&P/ASX All Ordinaries Index (ASX: XAO) is down 0.18%. These 3 ASX healthcare shares are a...

Respiri (ASX:RSH) has announced a binding agreement to acquire the business and assets of Orb Health Inc, a Texas-based provider of remote patient monitoring (RPM) and chronic care management (CCM) services. The acquisition, valued at US$9m...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

The S&P/ASX 200 fell 1.3% in October with small cap companies outperforming S&P Dow Jones Indices said financials led the gains in October and is up 30% YTD Ovanti rose 525% in October after appointment of former Zip US CFO Simon K...

Healthcare company Respiri (ASX: RSH) delivered strong growth in patient enrolments during the three months to the end of September across its chronic care management, remote patient monitoring, principal care management and transitional ca...

Telix Pharmaceuticals’ brain cancer diagnostic could leapfrog over its kidney cancer assay to be its second commercialised product Rhythm Biosciences still hopes to flush the bowel cancer ‘poo test’ into history Today’s quarterly reports s...

  ASX 200 hits record highs fuelled by Wall Street rally Tech and iron ore stocks lead gains Tyro sinks after government proposes new rules on debit surcharge   The ASX 200 index hit record highs on Tuesday after rising by 0.9%, eclipsin...

Cancer drug developer Chimeric Therapeutics eyes minimum $5 million raising ‘The next Telix’, Clarity gets FDA go-ahead for prostate cancer trial LTR Pharma fleshes out erectile dysfunction trial results   Cancer cell therapy house Chimer...

ASX gains  as energy and mining stocks rally Arcadium Lithium surges  after Rio acquisition, while GYG reports strong Q1 Hurricane Milton lands and pushes oil prices higher   The ASX gained ground by 0.3% on Thursday and neared its recor...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Medical technology specialist Respiri (ASX: RSH) has once again displayed the diversity of its business offering by reaching agreements to provide remote nursing support to care facilities in Hawaii. The company has entered into two individ...

‘Wheezo’ maker Respiri says a new US deal will help to propel the company to cash-flow break even by the end of the year Immutep reports further promising data from its head neck and shoulder cancer program Oncosil Medical targets the diff...

ASX up on Thursday, tech stocks rise boosted by NextDC Wodside Energy drops due to downgrade and oil price fall Iron Ore and coal slide, and Coronado sinks on production and cost issues   After a rough session on Wednesday, the ASX saw a...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

ANDHealth says the Covid-19 pandemic triggered far-reaching changes to Australia’s health system and how we manage respiratory illnesses Lumos Diagnostics has developed FebriDx to helps doctors quickly differentiate a viral from bacterial...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX 200’s rally was driven mainly by gold/silver and iron ore stocks Gold prices hit record high as China continues to buy bullion Asian markets rose due to high commodity prices and new stimulus measures    The ASX 200 index rose by +0....

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Asthma affects hundreds of millions of people globally While inhalers are effective, people are not taking them correctly Adherium addresses this problem, as we reached out to CEO Paul Mastoridis   It’s one of the most common chronic dise...

  ASX to lift on the back of Nasdaq rally US stocks rose on Friday as big techs reported solid results The US PCE Index however came in stronger than expected   Aussie shares are poised to open higher on Monday on the back of a Nasdaq ra...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

The ASX benchmark has ended Wednesday higher after positive inflation data 7 of 11 sectors in the green, IT ahead by circa +2pc Small caps led by Euro Manganese The local market has trimmed the CPI fat of this morning’s gains, after the...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Digital human developer Unith (ASX:UNT) posts 25 per cent lift in revenue for Q1 FY24 At the quarter’s end, the company held $2.7 in cash on hand Unith inked several new contracts over the quarter across the healthcare, e-lottery, and...

  Marjan Mikel – CEO – Respiri (ASX:RSH) offers the only remote patient monitoring program with remote wheeze detection for respiratory disorders as well as a broad number of serious chronic conditions.

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=7D2FBF3D-0297-B05B-8F498AF62BD096F8 –AFT Pharmaceuticals ((AFP)) by Edi...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The benchmark has sagged to -0.24% to close out the week with a world-weary sigh. Falling crude prices hobbled the Energy sector, dragging it 1.93% lower. Small caps winner Rubix Resources is feeling some neighbourly love, thanks to Allk...

Local markets have pedalled furiously since lunch to bring the benchmark to +0.35%. CBA posts record $10.2 billion profit off the back of ever-increasing interest rates. Small capper Perpetual stuns with a 50% spike after buying up land in...

A late surge from InfoTech pushed the benchmark to close at +0.07% InfoTech out front on +1.75%, ahead of Energy and Consumer Discretionary Huge news from Azure helped neighbour Errawarra into top spot for Small Caps   It’s the end of the...